Skip to Main Content

Paper Details

Residual Disease Burden After Neoadjuvant Therapy Among US Patients With High-Risk HER2-positive Early-Stage Breast Cancer: A Population Effectiveness Model.
Clin Breast Cancer
1
2022
Author NameAffiliation
Nathaniel HendrixHarvard T.H. Chan School of Public Health
David L VeenstraDepartment of Pharmacy, University of Washington
  • 1 - 2

Datasets

Release 1.2